AbbVie stock price forecast: bearish momentum persists as ABBV trades below major moving averages

Traders Union
All News
Business & Wealth
Companies
AbbVie down 0.17% at $210.77 today

Highlights

ABBV remains under seller pressure, trading below major moving averages and key resistance levels, indicating bearish momentum.
Momentum and trend indicators signal weak, oversold conditions, with mixed signals and low conviction for an imminent reversal.
The expected trading range for the next week is $209.50–$213.00, with limited upside and a higher probability of sideways or downward movement.

The research covers six dermatologic conditions. These are atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, hidradenitis suppurativa and alopecia areata.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

ABBV is trading at $210.77, which is currently below the MA-20 ($220.76), MA-50 ($221.98), and MA-200 ($215.62), indicating ongoing seller pressure in the short, medium, and long-term trend structures. The Ichimoku Kijun sits at $219.46, serving as immediate resistance above the current price, while near-term support is clustered around the MA-200 ($215.62) and key support appears at the MA-100 ($224.01); resistance levels are marked near the Ichimoku Kijun ($219.46) and MA-20 ($220.76).

Momentum indicators on D1 are mixed: MACD signals a sell, confirming weak momentum, while ADX shows a low reading near 16, indicating a lack of trend strength. RSI on D1 is below 40, CCI is negative, and both BBP and Stoch RSI are in oversold or neutral territory, suggesting sellers dominate but with possible exhaustion. Weekly, ABBV has risen $5.70 (2.78%) from last week's close at $205.07, now sitting near the very top of its weekly range with volatility amplitude at 4.78%. This marks a recovery from lower levels, but the divergence in daily momentum and oscillators underscores an uncertain short-term tone.

For the next week, the expected trading range is $209.50 to $213.00, which falls within typical volatility bands and keeps the price well off both the 52-week low ($164.39) and high ($244.81). Based on W1 signals—one Buy (SMA-50) out of four (RSI, ADX, MACD, MA-50)—the probability of a price increase is very low (less than 20%), with a price decrease more likely. The baseline scenario favors sideways movement within a tight corridor, while a bullish scenario would require a breakout above $219.46–$220.76 resistance. A bearish scenario could develop if the price falls below the $215.62–$210.77 support zone, potentially targeting lower weekly pivots.

Previously it was reported that AbbVie shares faced continued downside pressure amid weak momentum and a generally cautious outlook. As market dynamics evolve, investors should closely monitor for a decisive shift out of consolidation, as this may define AbbVie's next directional move.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.